A year after the signing of the Abraham Accords leaders and clinicians from Children's Hospital of Philadelphia (CHOP) hosted a meeting to share knowledge and research with pediatric experts from CHOP, the U.A.E. and Israel.
Beckwith-Wiedemann syndrome (BWS) is a complex multisystem overgrowth and cancer predisposition disorder that affects about 1 in 10,000 live births.
When A.L. was 11 years old, he complained of pain in his left hip. The pain subsided, but a week and a half later, A.L. came home crying and barely able to walk. The pain in his hip had become “excruciating.”
A collaborative team of researchers, including Dr. Stephan Grupp, recently presented preliminary data showing that a CRISPR-based gene-editing therapy for inherited blood disorders is safe and effective.
CHOP researchers have identified six biomarkers in the breath of children with COVID-19, laying the groundwork for a potential breathalyzer test.
Read a case study about a patient treated by physicians from the Pancreatic Disorders Program.
A new study involving CHOP researchers show blinatumomab is less toxic and as good or better than chemotherapy for high-risk relapsed B-ALL.
In May 2020, the U.S. Centers for Disease Control and Prevention (CDC) defined multi-system inflammatory syndrome in children (MIS-C), which was the diagnosis in this case.
Study is first to demonstrate how one specific combinational therapy may provide measurable benefits to patients with mitochondrial respiratory chain disorders, which currently lack FDA-approved therapies.
CHOP researchers describe different types of rashes they have seen in patients diagnosed with the COVID-19-related inflammatory syndrome.